Prognostic Factors in Mexican Patients with Patchy and Other Types of Alopecia Areata

Erick Alejandro Jiménez-Herrera Zamira Rios-Garza
María Luisa Peralta-Pedrero Fermin Jurado-Santa Cruz
Martha Alejandra Morales-Sánchez

Research and Education Unit, Centro Dermatológico “Dr. Ladislao de la Pascua, Mexico City, Mexico

Keywords

Alopecia areata · Adherence · Hair loss

Abstract

Introduction: Some clinical features have been associated with the progression and remission of alopecia areata (AA). We aim to determine possible prognostic factors in Mexican patients with AA. **Methods:** This prospective study of a 1-year follow-up included Mexican patients with a clinical diagnosis of AA. We evaluated disease activity with the SALT score at the first visit and 1-year follow-up; progression, no progression, and remission were defined according to score changes. We used multiple linear regression model to detect factors associated with progression and remission. **Results:** One hundred and four patients concluded the study. Ninety-seven patients (93.3%) had patchy AA. Fifteen patients showed disease progression and 89 no progression, of which 35 pa-

tients had remission. Body hair involvement was related to disease progression and adherence to treatment with disease remission and progression. **Conclusions:** Body hair involvement is related to poor prognosis. Adherence to treatment is a modifiable prognostic factor associated with the course of AA in Mexican patients.

© 2020 S. Karger AG, Basel

Introduction

Alopecia areata (AA) is an autoimmune disease and the second most common cause of non-scarring alopecia, behind androgenetic alopecia [1]. The prevalence of AA in general population is 0.2% and affects approximately 2% of Mexican population [2]. The main pathogenesis features are loss of “follicle immune privilege” and activation of CD8⁺ T cells against follicle autoanti-

Table 1. Sociodemographic and clinical features of patients with AA at the initial evaluation and loss of patients in the follow-up

	Initial evaluation (n = 120)	Final evaluation (n = 104)	p value
<i>Sociodemographic features</i>			
Sex, n (%)			
Female	70 (58.3)	44 (42.3)	0.71
Male	50 (41.7)	60 (57.7)	
Age, years (median [range])	25.5 (75)	25.5 (75)	0.75
<i>Clinical features</i>			
Type of AA, n (%)			
Patchy	112 (93.3)	97 (93.3)	0.98
Ophiasis	2 (1.7)	2 (1.9)	
Totalis	4 (3.3)	4 (3.8)	
Universalis	2 (1.7)	1 (1)	
Disease duration, years (median [range])	1 (27)	1 (27)	0.98
Age at disease onset, years (mean $\pm$ SD)	24.8 $\pm$ 15.4	24.8 $\pm$ 15.8	0.98
Initial SALT score (median [range])	6.5 (100)	7.0 (100)	0.27
Body score, n (%)			
B0	98 (81.7)	86 (82.7)	0.44
B1	18 (15)	15 (14.4)	
B2	4 (3.3)	3 (2.9)	
Nail score, n (%)			
N0	104 (86.7)	90 (86.5)	0.95
N1	12 (10)	11 (10.6)	
N1a	4 (3.3)	3 (2.9)	
Episodes, n (%)			
1 episode	82 (68.3)	73 (70.1)	0.71
2 episodes	28 (22.3)	21 (20.2)	
3 episodes	5 (4.1)	5 (4.8)	
≥ 4 episodes	5 (4.1)	5 (4.8)	
Ungueal involvement, n (%)	20 (16.7)	18 (17.3)	0.51
Body hair involvement, n (%)	24 (20)	20 (19.2)	0.59

gens [3]. Disease severity is assessed by the Severity Alopecia Tool (SALT) score, which evaluates hair loss extension in the scalp and body. AA is associated with genetic factors and other autoimmune diseases: systemic lupus erythematosus (SLE), vitiligo, and psoriasis [4].

The course of AA is unpredictable. Eighty percent of patients with AA and low hair extension could present spontaneous remission. Some clinical features reported to increase disease severity are chronic disease activity, extensive hair loss, concomitant autoimmune disease, atopic dermatitis, and ungueal involvement [1]. However, factors that influence course and prognosis in patients under treatment are controversial. Studies of prognostic factors in Mexican patients with AA under treatment have not been published. Therefore, we aim to determine possible prognostic factors in Mexican patients with AA.

Materials and Methods

Patient Selection

This prospective study included patients with a clinical diagnosis of AA of any age and gender, attending to “Dr. Ladislao de la Pascua” Dermatology Center from February 2017 to December 2017. Then, the patients were followed up for 1 year. Patients must have disease activity, defined as the presence of at least 2 of the following criteria: positive pull test with gentle traction of 40–60 hair follicles from 3 different parts of the plaque and loss of >10 hair follicles, puffy consistency of the plaque, and a trichoscopy with “exclamation hair follicle sign,” hair follicle dystrophy, and black dots. Exclusion criteria were loss to follow-up and not agreeing to participate.

Sociodemographic Features

In the first visit, patients answered a structured interview evaluating sociodemographic features and family and personal history of AA, vitiligo, atopic dermatitis, psoriasis, systemic lupus erythematosus, thyroid disease, irritable bowel disease, rheumatoid arthritis, di-

Table 2. Clinical features of the progression and no progression groups (N = 104)

	Progression (n = 15)	No progression (n = 89)	p value
Type of AA, n (%)			
Patchy	12 (80)	85 (95.5)	0.03
Ophiasis	2 (13.3)	0 (0)	
Totalis	1 (6.7)	3 (3.4)	
Universalis	0 (0)	1 (1.1)	
Age at disease onset, years (mean ± SD)	16.4±13.2	26.4±15.8	0.027
Disease duration, years (median [range])	2 (23)	1 (27)	0.29
Body hair involvement, n (%)	8 (53.3)	12 (13.4)	<0.01
Ungueal involvement, n (%)	5 (33.3)	13 (14.6)	0.086
Episodes, n (%)			
1 episode	11 (73.3)	62 (69.7)	0.363
2 episodes	3 (20)	18 (20.2)	
3 episodes	0 (0)	5 (5.6)	
≥4 episodes	1 (6.7)	4 (4.5)	
Treatment, n (%)			
Topical steroids	9 (69.2)	66 (77.6)	0.507
Intralesional steroids	7 (53.8)	22 (25.6)	0.081
Systemic steroids	5 (38.5)	7 (8.1)	0.002
Topical psoralens	5 (38.5)	15 (17.4)	0.080
Phototherapy	1 (7.7)	3 (3.5)	0.475
Retinoids	0 (0)	3 (3.5)	0.496
Adherence to treatment, n (%)			
100%	5 (33.3)	42 (47.1)	0.43
90%	4 (26.6)	34 (38.2)	
89–60%	4 (26.6)	12 (13.4)	
59–30%	1 (6.6)	0 (0)	
29–10%	0 (0)	1 (1.1)	
<10%	1 (6.6)	0 (0)	

abetes mellitus (DM), systemic arterial hypertension, obesity, cardiovascular disease, toxicomania, and allergies. In the second visit at 1-year follow up, we investigated a new diagnosis of vitiligo, atopic dermatitis, asthma, allergic rhinitis, urticaria, autoimmune disease, psoriasis, thyroid disease, DM, hypertension, obesity, and dyslipidemia. If positive, laboratories and treatments were recorded.

Clinical Features of AA

Age at disease onset, disease duration, number of activity episodes, hair loss pattern, treatments, and ungueal and body hair involvement were registered. Iconographic control was taken according to AA Investigational Assessment Guidelines Criteria [5]. One dermatologist evaluated disease severity with the SALT score at first and 1 year later visits. Patients were divided into disease progression and no progression groups according to the SALT score changes. We defined disease progression as an increase in the 1-year SALT score compared to initial SALT score and no progression a 1-year SALT score with decrease or without changes compared to initial SALT score. Patients with a 1-year SALT score of 0 were defined as remission. Adherence to treatment was evaluated by a structured questionnaire, and we defined good adherence to treatment a score of 90–100% and bad adherence <90%.

Statistical Analysis

The distribution of variables was assessed using the Kolmogorov-Smirnov test. We reported abnormally distributed variables with median and ranges, normally distributed quantitative variables with mean and SD, and qualitative variables with percentages. We used the Mann Whitney U test to compare abnormally distributed variables and the χ^2 test to correlate disease progression, no progression, and remission groups. Variables with statistical significance were included in a multiple linear regression model. Finally, we assessed variables with statistical significance with a proportional risk model using the Cox regression model and graphing with the Kaplan-Meier curves. We considered $p < 0.05$ as statistically significant. We analyzed data with SPSS version 25.

Results

One hundred and twenty patients were included in the study, and 16 patients were unable to return to the Dermatology Center (13.3% loss of patients). Sociodemographic and clinical features are shown in Table 1.

Table 3. Sociodemographic and clinical features of the progression and remission groups (N = 50)

	Progression (n = 15)	Remission (n = 35)	p value
<i>Sociodemographic features</i>			
Sex, n (%)			
Female	12 (80)	15 (42.9)	0.12
Male	3 (20)	20 (57.1)	
Age, years (median [range])	24 (44)	35 (41)	0.06
Family history, n (%)			
AA	3 (20)	10 (28.6)	0.53
Atopic dermatitis, asthma, allergic rhinitis, and urticaria	1 (6.7)	0 (0)	0.33
Diabetes mellitus	8 (53.3)	0 (0)	0.53
Systemic arterial hypertension	7 (46.7)	0 (0)	0.76
Thyroid disease	2 (13.3)	0 (0)	0.93
Autoimmune diseases ^a	4 (26.6)	3 (8.5)	0.61
Personal history, n (%)			
Vitiligo	0 (0)	3 (8.6)	0.24
Atopic dermatitis, asthma, allergic rhinitis, and urticaria	3 (20)	3 (8.6)	0.26
Thyroid disease	1 (6.7)	0 (0)	0.12
Diabetes mellitus	0 (0)	0 (0)	1
Systemic arterial hypertension	0 (0)	0 (0)	1
Dyslipidemia	1 (6.7)	4 (11.4)	0.61
Autoimmune diseases ^a	1 (6.7)	0 (0)	0.12
Smoking, n (%)			
Active	3 (20)	9 (25.7)	0.67
Inactive	2 (13.3)	6 (17.1)	0.73
Alcoholism	5 (33.3)	16 (45.7)	0.42
<i>Clinical features</i>			
Disease duration, years (median [range])	2 (23)	1 (27)	0.29
Age at disease onset, years (mean±SD)	16.4±13.2	28.1±13.8	0.01
Initial SALT score (median [range])	18 (91)	4 (15)	<0.01
Body score, n (%)			<0.01
B0	7 (46.73)	33 (94.3)	0.25
B1	8 (53.3)	2 (5.7)	
B2	0 (0)	0 (0)	
Nail score, n (%)			
N0	12 (80)	32 (91.4)	
N1	3 (20)	3 (8.6)	
N1a	0 (0)	0 (0)	
Final SALT score (median [range])	20.5 (96)	0 (0)	<0.01
Body score, n (%)			<0.01
B0	7 (46.73)	33 (94.3)	0.01
B1	8 (53.3)	2 (5.7)	
B2	0 (0)	0 (0)	
Nail score, n (%)			
N0	10 (66.7)	32 (91.4)	
N1	5 (33.3)	3 (8.6)	
N1a	0 (0)	0 (0)	
Episodes, n (%)			
1 episode	11 (73.3)	27 (43.3)	0.80
2 episodes	3 (20)	5 (15.4)	
3 episodes	0 (0)	2 (14.3)	
≥4 episodes	1 (6.7)	1 (2.9)	
Type of AA, n (%)			
Patchy	12 (80)	35 (100)	<0.01
Ophiasis	2 (13.3)	0 (0)	
Totalis	1 (6.7)	0 (0)	

Table 3 (continued)

	Progression (<i>n</i> = 15)	Remission (<i>n</i> = 35)	<i>p</i> value
Universalis	0 (0)	0 (0)	
Ungueal involvement, <i>n</i> (%)	5 (33.3)	3 (8.6)	0.03
Body hair involvement, <i>n</i> (%)	8 (53.3)	2 (5.7)	<0.01
Treatment, <i>n</i> (%)			
Topical steroid	9 (69.2)	24 (72.7)	0.81
Intralesional steroid	7 (53.8)	6 (17.6)	0.03
Systemic steroid	5 (38.5)	2 (5.9)	<0.01
Topical psoralen	5 (38.5)	4 (11.8)	0.04
Topical retinoid	1 (7.7)	1 (2.9)	0.53
Phototherapy	0 (0)	0 (0)	0.1
Adherence to treatment, <i>n</i> (%)			
100%	5 (33.3)	21 (60)	0.02
90%	4 (26.6)	10 (28.5)	
89–60%	4 (26.6)	3 (8.5)	
59–30%	1 (6.6)	0 (0)	
29–10%	0 (0)	1 (2.8)	
<10%	1 (6.6)	0 (0)	

^a Psoriasis, systemic lupus erythematosus, rheumatoid arthritis, bullous diseases, and vasculitis.

Clinical Features of Disease

Most of the patients had patchy AA (93.3%) and low initial SALT score (median 7 points, range 100). The mean age at disease onset was 24.8 ± 15.8 years. Patients with patchy AA showed a mean age at disease onset of 25.55 ± 15.5 years and median disease evolution of 3.15 (range 1–27), 69% one episode, and 78% good adherence to treatment. These clinical features were not statistically different compared to other types of AA.

Body hair involvement was found in 15 patients with patchy AA (15.5%), 1 patient with totalis AA (25%), 1 patient with ophiasis AA (50%), and 1 patient with universalis AA (100%) without statistically significant differences ($p = 0.08$).

Fifteen patients had disease progression and 89 patients no progression. Eighty percent of patients with disease progression had patchy AA, median disease duration of 2 years (range 23), mean age at disease onset of 16.4 ± 13.2 years, 53.3% had body hair involvement, and 59.9% good adherence to treatment. Clinical and treatment features of these groups are shown in Table 2.

Thirty-five patients from no progression group had disease remission. All patients presented with patchy AA, median disease duration of 1 year (range 27), mean age at disease onset of 28.1 ± 13.8 years, and low prevalence of ungueal and body hair involvement (8.6 and 5.7%, re-

spectively). Clinical and treatment features of the remission group are shown in Table 3.

In both groups, the main causes of bad adherence to treatment were no time and forgetting to apply the treatment and irritation with topical medications. Patients with worse adherence to treatment in both groups were under treatment with topical steroids, minoxidil, and psoralens.

Factors Associated with Disease Course

Sociodemographic features were not associated with disease progression or remission. Comparisons of clinical features between disease progression and no progression groups showed that the earliest age at disease onset and body hair involvement were more frequent in patients with progression ($p = 0.02$ and $p < 0.01$, respectively). Other clinical and treatment features did not show statistically significant differences (Table 2).

Subanalysis of progression and remission groups showed significant differences with age (median 24 vs. 35 years, $p = 0.06$), age at disease onset (median 8.5 vs. 31 years, $p = 0.01$), ungueal involvement (33.3 vs. 8.6%, $p = 0.03$), body hair involvement (53.3 vs. 5.7%, $p < 0.01$), and treatment with intralesional steroid (53.8 vs. 17.6%, $p = 0.03$), systemic corticotherapy (38.5 vs. 5.9%, $p < 0.01$), and topical psoralen (38.5 vs. 11.8%, $p = 0.04$). Good adherence to treatment was

Table 4. Multiple linear regression model for factors associated with disease progression

Variable	N	%	χ^2 , <i>p</i> value	<i>B</i>	95% CI	<i>p</i> value
Body hair involvement						
Present	8/15	53.3				
Absent	7/15	46.7	<0.01	0.798	0.42 to 1.17	<0.01
Body score (SALT score)						
B0	7/15	46.7				
B1	8/15	53.3				
B2	0/15	0.0	<0.01	0.468	0.16 to 0.78	0.03
Adherence to treatment						
100%	5/15	33.3				
90%	4/15	26.6				
89–60%	4/15	26.6				
59–30%	1/15	6.6				
29–10%	0/15	0.0				
<10%	1/15	6.6	<0.01	–0.88	–0.15 to –0.021	0.01

Fig. 1. Body hair involvement in AA patients with disease progression with Cox regression.

more prevalent in the remission group than in the progression group (85.3 vs. 59.9%, $p = 0.02$) (Table 3).

Factors with statistical differences between progression and no progression groups were included in a multiple linear regression model. Body hair involvement according to body score of SALT score and adherence to treatment were associated with disease progression (Table 4). The Cox regression analysis showed that body hair involvement was related to disease progression during the follow up ($p = 0.04$; OR 1.26, 95% CI: 1.04–12.0) (Fig. 1, 2).

Finally, we included statistical relevant factors from the subanalysis of patients with disease remission in the multiple linear regression model. Body hair involvement showed a negative association with disease remission (Table 5).

Fig. 2. Kaplan-Meier curves for body hair involvement.

Discussion

AA is an autoimmune disease that causes significant psychological and cosmetic impact on patients. The frequency in Mexican dermatologic consult is 1% [6]. AA has a heritable basis, and specific genes have been associated with disease severity and concomitant diseases. We evaluated the family history of patients with AA including inflammatory and autoimmune disease, which did not show any relevance on disease course during follow-up. Patients with disease progression had a higher prevalence of positive family history of atopic dermatitis, DM, sys-

Table 5. Multiple linear regression model for factors associated with disease remission

Variable	N	%	χ^2 , <i>p</i> value	<i>B</i>	95% CI	<i>p</i> value
Body hair involvement						
Present	2/35	5.7				
Absent	33/35	94.3	0.013	−0.295	−0.530 to −0.059	0.015

temic arterial hypertension, and thyroid disease compared to the remission group, which were not statistically significant.

The relevance of a positive family history of AA in disease course is controversial. Studies report that 10–51.6% of patients with AA have a personal history of a first-degree relative with AA, which is related to disease onset before 30 years of age [7]. In the present study, 10–24% of patients had a family history of AA, which did not affect the disease course. The small size of the progression and remission groups and a low prevalence of this family history could explain our results.

Several factors have been reported to determine disease severity in AA. Previous studies have found that low hair loss during activity episodes is related to a spontaneous remission, with 80% of patients with complete regrowth in 1 year. Therefore, ophiasis or totalis AA show a high prevalence of progression [8]. In our study, we did not find any relation between progression and type of AA in the multiple linear regression model. Similar results have been reported in a recent study [9].

We found that disease onset at an early age and AA types with extensive hair loss were more prevalent in patients with progression than in no progression group, with similar results reported previously [10, 11]. Lyakhovitsky et al. [10] found that patients with disease onset at an early age had a higher prevalence of disease severity. However, some authors have not found these associations [9] and remain controversial.

In our study, body hair involvement was the most important prognostic factor associated with disease progression. This clinical feature has been related to extensive hair loss, progression, relapses, and a recalcitrant disease [1]. Vañó-Galván et al. [12] described clinical features associated with bad prognosis in 80 patients with universalis AA and 52 patients with totalis AA. They found that universalis AA and family history of AA were the most important factors associated with a bad prognosis (OR 4.77, 95% CI: 0.6–31, and OR 3.73, 95% CI: 0.7–42.8, respectively). These results have been reported by other studies [13]. In the present study, body hair involvement

was present in all types of AA. We proposed that this clinical feature could be an independent prognostic factor associated with progression in Mexican patients with AA. To our concern, studies describing the molecular mechanisms and clinical relevance of body hair involvement in patients with AA have not been published. This prognostic factor could be considered in the therapeutic approach and future research of patients with recalcitrant AA in Mexico and other countries.

Treatment of AA has been under active research in the last decade, and numerous novel therapeutic options have been published, especially for recalcitrant AA. However, corticotherapy is still one of the most useful treatments for AA. Our patients with disease progression had more prevalence of systemic corticotherapy in comparison with no progression patients, probably related to extensive hair loss and no response to other treatment modalities. We found that corticotherapy and adherence to treatment were not statistically related to disease progression. However, when we considered disease remission from no progression group, we found a higher prevalence of good adherence to treatment in the remission group compared to the progression group. Good adherence to treatment showed a negative statistical correlation with disease progression in multiple linear regression model. Patient orientation about clinical and treatment features of AA could improve adherence to treatment and prognosis [14]. Besides, we have reported that depression, anxiety, and suicide affect the quality of life and prognosis of patients with AA [15]. We propose that a good orientation, treatment adaptability according to patients' occupations, and listening to their requirements in dermatologic consultation could increase the probability to reach remission.

Conclusions

Body hair involvement is related to poor prognosis. Adherence to treatment is a modifiable prognostic factor associated with the course of AA in Mexican patients.

Acknowledgements

The authors thank Germán Guerrero-Oliva, MD, and Quetzalli Chirino-Castillo, MD, for their work in recruiting participants.

Statement of Ethics

This study was approved by local ethics committee according to the Helsinki Declaration. Informed consent was obtained from all patients.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No funding sources were employed in this study.

Author Contributions

E.A.J.-H. conceived the idea of the manuscript and contributed to the analysis and interpretation of data and drafting the manuscript. Z.R.-G. contributed to include patients in the study, interview patients, and acquisition of data for statistical analysis. M.L.P.-P. contributed to methodological design, analysis of data, and final approval of the version to be published. F.J.-S.C. developed the theoretical formalisms and conception of the work and revised and approved the final version of the work. M.A.M.-S. was responsible for study design, implementation, and enrollment of participants; analyzed and interpreted the data; reviewed the first draft; and approved the final manuscript.

References

- 1 Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. *Nat Rev Dis Primers*. 2017;3(3):17011–3.
- 2 Jabbari A, Petukhova L, Cabral RM, Clynes R, Christiano AM. Genetic basis of alopecia areata: a roadmap for translational research. *Dermatol Clin*. 2013;31(1):109–17.
- 3 Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. *Autoimmun Rev*. 2015;14(2):81–9.
- 4 Fricke ACV, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. *Clin Cosmet Investig Dermatol*. 2015;8:397–403.
- 5 Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines: part II. National Alopecia Areata Foundation. *J Am Acad Dermatol*. 2004;51(3):440–7.
- 6 Martínez-Suárez, H. Alopecia areata. *Dermatol Rev Mex*. 2015;59:395–405.
- 7 Rocha J, Ventura F, Vieira AP, Pinheiro AR, Fernandes S, Brito C. [Alopecia areata: a retrospective study of the paediatric dermatology department (2000–2008)]. *Acta Med Port*. 2011;24(2):207–14.
- 8 Selmi C, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. *J Autoimmun*. 2012;39(4):272–84.
- 9 Uchiyama M, Egusa C, Hobo A, Irisawa R, Yamazaki M, Tsuboi R. Multivariate analysis of prognostic factors in patients with rapidly progressive alopecia areata. *J Am Acad Dermatol*. 2012;67(6):1163–73.
- 10 Lyakhovitsky A, Aronovich A, Gilboa S, Baum S, Barzilai A. Alopecia areata: a long-term follow-up study of 104 patients. *J Eur Acad Dermatol Venereol*. 2019;33(8):1602–9.
- 11 Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. *Int J Dermatol*. 1996;35(1):22–7.
- 12 Vañó-Galván S, Fernández-Crehuet P, Girmalt R, García-Hernández MJ, Rodrigues-Barata R, Arias-Santiago S, et al. Alopecia areata totalis and universalis: a multicenter review of 132 patients in Spain. *J Eur Acad Dermatol Venereol*. 2017;31(3):550–6.
- 13 Jang YH, Hong NS, Moon SY, Eun DH, Lee WK, Chi SG, et al. Long-term prognosis of alopecia totalis and alopecia universalis: a longitudinal study with more than 10 years of follow-up: better than reported. *Dermatology*. 2017;233(2-3):250–6.
- 14 Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. *Am J Med Sci*. 2016;351(4):387–99.
- 15 Vélez-Muñoz Rd C, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-Sánchez MA. Psychological profile and quality of life of patients with alopecia areata. *Skin Appendage Disord*. 2019;5(5):293–298.